
ZYPREXA [®] ZYDIS [®] Olanzapine Orally Disintegrating Tablets
ZYPREXA [®] IntraMuscular Olanzapine for Injection WARNING
Increased Mortality in Elderly Patients with Dementia-Related Psychosis — Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. ZYPREXA (olanzapine) is not approved for the treatment of patients with dementia-related psychosis (<i>see</i> WARNINGS).
DESCRIPTION ZYPREXA (olanzapine) is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10 <i>H</i> -thieno[2,3- <i>b</i>] [1,5]benzodiazepine. The molecular formula is $C_{17}H_{20}N_4S$, which corresponds to a molecular weight of 312.44. The chemical structure is:



- 27 Olanzapine is a yellow crystalline solid, which is practically insoluble in water.
- 28 ZYPREXA tablets are intended for oral administration only.
- Each tablet contains olanzapine equivalent to 2.5 mg (8 µmol), 5 mg (16 µmol), 7.5 mg
- 30 (24 µmol), 10 mg (32 µmol), 15 mg (48 µmol), or 20 mg (64 µmol). Inactive ingredients are
- 31 carnauba wax, crospovidone, hydroxypropyl cellulose, hypromellose, lactose, magnesium
- 32 stearate, microcrystalline cellulose, and other inactive ingredients. The color coating contains
- 33 Titanium Dioxide (all strengths), FD&C Blue No. 2 Aluminum Lake (15 mg), or Synthetic Red
- Iron Oxide (20 mg). The 2.5, 5, 7.5, and 10 mg tablets are imprinted with edible ink which
- 35 contains FD&C Blue No. 2 Aluminum Lake.

- 36 ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) is intended for oral administration 37 only.
- 38 Each orally disintegrating tablet contains olanzapine equivalent to 5 mg (16 µmol), 10 mg
- 39 $(32 \,\mu mol)$, 15 mg (48 $\mu mol)$ or 20 mg (64 $\mu mol)$. It begins disintegrating in the mouth within
- 40 seconds, allowing its contents to be subsequently swallowed with or without liquid.
- 41 ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) also contains the following inactive
- 42 ingredients: gelatin, mannitol, aspartame, sodium methyl paraben and sodium propyl paraben.
- 43 ZYPREXA IntraMuscular (olanzapine for injection) is intended for intramuscular use only.
- 44 Each vial provides for the administration of 10 mg (32 µmol) olanzapine with inactive
- 45 ingredients 50 mg lactose monohydrate and 3.5 mg tartaric acid. Hydrochloric acid and/or
- 46 sodium hydroxide may have been added during manufacturing to adjust pH.
- 47

CLINICAL PHARMACOLOGY

48 Pharmacodynamics

- 49 Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following 50 receptors: serotonin 5HT_{2A/2C}, 5HT₆, (K_i=4, 11, and 5 nM, respectively), dopamine D_{1-4}
- 51 (K_i=11-31 nM), histamine H₁ (K_i=7 nM), and adrenergic α_1 receptors (K_i=19 nM). Olanzapine is
- 52 an antagonist with moderate affinity binding for serotonin $5HT_3$ (K_i=57 nM) and muscarinic M₁₋₅
- 53 (K_i=73, 96, 132, 32, and 48 nM, respectively. Olanzapine binds weakly to GABA_A, BZD, and 54
- β adrenergic receptors (K_i>10 μ M).
- 55 The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia,
- is unknown. However, it has been proposed that this drug's efficacy in schizophrenia is mediated 56 through a combination of dopamine and serotonin type $2(5HT_2)$ antagonism. The mechanism of 57
- 58 action of olanzapine in the treatment of acute manic episodes associated with Bipolar I Disorder
- 59 is unknown.
- 60 Antagonism at receptors other than dopamine and $5HT_2$ may explain some of the other
- therapeutic and side effects of olanzapine. Olanzapine's antagonism of muscarinic M_{1-5} receptors 61
- may explain its anticholinergic-like effects. Olanzapine's antagonism of histamine H_1 receptors 62
- 63 may explain the somnolence observed with this drug. Olanzapine's antagonism of adrenergic α_1
- 64 receptors may explain the orthostatic hypotension observed with this drug.

65 **Pharmacokinetics**

66 **Oral Administration**

- Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours 67
- 68 following an oral dose. It is eliminated extensively by first pass metabolism, with approximately
- 69 40% of the dose metabolized before reaching the systemic circulation. Food does not affect the
- 70 rate or extent of olanzapine absorption. Pharmacokinetic studies showed that ZYPREXA tablets
- 71 and ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) dosage forms of olanzapine are 72 bioequivalent.
- 73 Olanzapine displays linear kinetics over the clinical dosing range. Its half-life ranges from 21 to 74 54 hours (5th to 95th percentile; mean of 30 hr), and apparent plasma clearance ranges from
- 75 12 to 47 L/hr (5th to 95th percentile; mean of 25 L/hr).
- 76 Administration of olanzapine once daily leads to steady-state concentrations in about one week
- 77 that are approximately twice the concentrations after single doses. Plasma concentrations,
- 78 half-life, and clearance of olanzapine may vary between individuals on the basis of smoking
- 79 status, gender, and age (see Special Populations).
- 80 Olanzapine is extensively distributed throughout the body, with a volume of distribution of
- 81 approximately 1000 L. It is 93% bound to plasma proteins over the concentration range of 7 to
- 82 1100 ng/mL, binding primarily to albumin and α_1 -acid glycoprotein.

- Metabolism and Elimination Following a single oral dose of 14 C labeled olanzapine, 7% of 83
- 84 the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine
- 85 is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and
- 86 feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total 87 radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major
- 88 circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the
- 89 concentration of olanzapine, and 4'-N-desmethyl olanzapine, present at steady state at 31% of the
- 90 concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations 91 observed.
- 92 Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary
- 93 metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the
- 94 flavin-containing monooxygenase system are involved in olanzapine oxidation.
- 95 CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo, because the
- 96 clearance of olanzapine is not reduced in subjects who are deficient in this enzyme.

97 Intramuscular Administration

- 98 ZYPREXA IntraMuscular results in rapid absorption with peak plasma concentrations
- 99 occurring within 15 to 45 minutes. Based upon a pharmacokinetic study in healthy volunteers, a
- 100 5 mg dose of intramuscular olanzapine for injection produces, on average, a maximum plasma
- 101 concentration approximately 5 times higher than the maximum plasma concentration produced
- 102 by a 5 mg dose of oral olanzapine. Area under the curve achieved after an intramuscular dose is
- 103 similar to that achieved after oral administration of the same dose. The half-life observed after
- 104 intramuscular administration is similar to that observed after oral dosing. The pharmacokinetics
- 105 are linear over the clinical dosing range. Metabolic profiles after intramuscular administration are 106 qualitatively similar to metabolic profiles after oral administration.

107 **Special Populations**

- 108 Renal Impairment — Because olanzapine is highly metabolized before excretion and only
- 109 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact
- 110 on the pharmacokinetics of olanzapine. The pharmacokinetic characteristics of olanzapine were
- 111 similar in patients with severe renal impairment and normal subjects, indicating that dosage
- 112 adjustment based upon the degree of renal impairment is not required. In addition, olanzapine is
- 113 not removed by dialysis. The effect of renal impairment on metabolite elimination has not been 114 studied.
- 115 Hepatic Impairment — Although the presence of hepatic impairment may be expected to
- 116 reduce the clearance of olanzapine, a study of the effect of impaired liver function in
- subjects (n=6) with clinically significant (Childs Pugh Classification A and B) cirrhosis revealed 117 118 little effect on the pharmacokinetics of olanzapine.
- 119 Age — In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine 120 was about 1.5 times greater in elderly (>65 years) than in non-elderly subjects (≤ 65 years).
- 121 Caution should be used in dosing the elderly, especially if there are other factors that might
- 122 additively influence drug metabolism and/or pharmacodynamic sensitivity (see DOSAGE AND
- 123 ADMINISTRATION).
- 124 Gender — Clearance of olanzapine is approximately 30% lower in women than in men. There 125 were, however, no apparent differences between men and women in effectiveness or adverse 126 effects. Dosage modifications based on gender should not be needed.
- 127 Smoking Status — Olanzapine clearance is about 40% higher in smokers than in nonsmokers, 128 although dosage modifications are not routinely recommended.
- 129 Race — In vivo studies have shown that exposures are similar among Japanese, Chinese and
- 130 Caucasians, especially after normalization for body weight differences. Dosage modifications for
- 131 race are, therefore, not recommended.

132 <u>Combined Effects</u> — The combined effects of age, smoking, and gender could lead to

133 substantial pharmacokinetic differences in populations. The clearance in young smoking males,

134 for example, may be 3 times higher than that in elderly nonsmoking females. Dosing

- modification may be necessary in patients who exhibit a combination of factors that may result in slower metabolism of olanzapine (*see* DOSAGE AND ADMINISTRATION).
- 137 For specific information about the pharmacology of lithium or valproate, refer to the
- 138 CLINICAL PHARMACOLOGY section of the package inserts for these other products.

139 Clinical Efficacy Data

140 Schizophrenia

141 The efficacy of oral olanzapine in the treatment of schizophrenia was established in

142 2 short-term (6-week) controlled trials of inpatients who met DSM III-R criteria for

- schizophrenia. A single haloperidol arm was included as a comparative treatment in one of the
- 144 two trials, but this trial did not compare these two drugs on the full range of clinically relevant 145 doses for both.
- 146 Several instruments were used for assessing psychiatric signs and symptoms in these studies,
- among them the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general
- 148 psychopathology traditionally used to evaluate the effects of drug treatment in schizophrenia. The
- 149 BPRS psychosis cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and
- 150 unusual thought content) is considered a particularly useful subset for assessing actively
- 151 psychotic schizophrenic patients. A second traditional assessment, the Clinical Global
- 152 Impression (CGI), reflects the impression of a skilled observer, fully familiar with the
- 153 manifestations of schizophrenia, about the overall clinical state of the patient. In addition,
- 154 two more recently developed scales were employed; these included the 30-item Positive and 155 Negative Symptoms Scale (PANSS), in which are embedded the 18 items of the BPRS, and the
- Scale for Assessing Negative Symptoms (SANS). The trial summaries below focus on the
- following outcomes: PANSS total and/or BPRS total; BPRS psychosis cluster; PANSS negative
- subscale or SANS; and CGI Severity. The results of the trials follow:
- (1) In a 6-week, placebo-controlled trial (n=149) involving two fixed olanzapine doses of 1 and
 10 mg/day (once daily schedule), olanzapine, at 10 mg/day (but not at 1 mg/day), was superior to
 placebo on the PANSS total score (also on the extracted BPRS total), on the BPRS psychosis
 cluster on the PANSS Negative subscale, and on CCI Severity.
- 162 cluster, on the PANSS Negative subscale, and on CGI Severity.
- 163 (2) In a 6-week, placebo-controlled trial (n=253) involving 3 fixed dose ranges of olanzapine
- 164 $(5 \pm 2.5 \text{ mg/day}, 10 \pm 2.5 \text{ mg/day}, \text{ and } 15 \pm 2.5 \text{ mg/day})$ on a once daily schedule, the
- 165 two highest olanzapine dose groups (actual mean doses of 12 and 16 mg/day, respectively) were
- superior to placebo on BPRS total score, BPRS psychosis cluster, and CGI severity score; the
- highest olanzapine dose group was superior to placebo on the SANS. There was no clear advantage for the high dose group over the medium dose group
- advantage for the high dose group over the medium dose group.
- 169 Examination of population subsets (race and gender) did not reveal any differential170 responsiveness on the basis of these subgroupings.
- 171 In a longer-term trial, adult outpatients (n=326) who predominantly met DSM-IV criteria for
- schizophrenia and who remained stable on olanzapine during open label treatment for at least
- 173 8 weeks were randomized to continuation on their current olanzapine doses (ranging from 10 to
- 174 20 mg/day) or to placebo. The follow-up period to observe patients for relapse, defined in terms
- of increases in BPRS positive symptoms or hospitalization, was planned for 12 months, however,
- 176 criteria were met for stopping the trial early due to an excess of placebo relapses compared to
- olanzapine relapses, and olanzapine was superior to placebo on time to relapse, the primary
 outcome for this study. Thus, olanzapine was more effective than placebo at maintaining efficacy
- in patients stabilized for approximately 8 weeks and followed for an observation period of up to
- 180 8 months.

181 **Bipolar Disorder**

182 Monotherapy — The efficacy of oral olanzapine in the treatment of acute manic or mixed 183 episodes was established in 2 short-term (one 3-week and one 4-week) placebo-controlled trials in patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. 184

185 These trials included patients with or without psychotic features and with or without a 186 rapid-cycling course.

187 The primary rating instrument used for assessing manic symptoms in these trials was the 188 Young Mania Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess 189 the degree of manic symptomatology (irritability, disruptive/aggressive behavior, sleep, elevated 190 mood, speech, increased activity, sexual interest, language/thought disorder, thought content,

191 appearance, and insight) in a range from 0 (no manic features) to 60 (maximum score). The

192 primary outcome in these trials was change from baseline in the Y-MRS total score. The results 193 of the trials follow:

194 (1) In one 3-week placebo-controlled trial (n=67) which involved a dose range of olanzapine

195 (5-20 mg/day, once daily, starting at 10 mg/day), olanzapine was superior to placebo in the

196 reduction of Y-MRS total score. In an identically designed trial conducted simultaneously with

197 the first trial, olanzapine demonstrated a similar treatment difference, but possibly due to sample

198 size and site variability, was not shown to be superior to placebo on this outcome.

199 (2) In a 4-week placebo-controlled trial (n=115) which involved a dose range of olanzapine 200 (5-20 mg/day, once daily, starting at 15 mg/day), olanzapine was superior to placebo in the

201 reduction of Y-MRS total score.

202 (3) In another trial, 361 patients meeting DSM-IV criteria for a manic or mixed episode of 203 bipolar disorder who had responded during an initial open-label treatment phase for about two 204 weeks, on average, to olanzapine 5 to 20 mg/day were randomized to either continuation of 205 olanzapine at their same dose (n=225) or to placebo (n=136), for observation of relapse. 206 Approximately 50% of the patients had discontinued from the olanzapine group by day 59 and

207 50% of the placebo group had discontinued by day 23 of double-blind treatment. Response

- 208 during the open-label phase was defined by having a decrease of the Y-MRS total score to ≤ 12
- 209 and HAM-D 21 to ≤ 8 . Relapse during the double-blind phase was defined as an increase of the 210 Y-MRS or HAM-D 21 total score to \geq 15, or being hospitalized for either mania or depression. In

211 the randomized phase, patients receiving continued olanzapine experienced a significantly longer 212 time to relapse.

213 Combination Therapy — The efficacy of oral olanzapine with concomitant lithium or valproate 214 in the treatment of acute manic episodes was established in two controlled trials in patients who

215 met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. These trials

216 included patients with or without psychotic features and with or without a rapid-cycling course.

217 The results of the trials follow:

218 (1) In one 6-week placebo-controlled combination trial, 175 outpatients on lithium or valproate 219 therapy with inadequately controlled manic or mixed symptoms (Y-MRS ≥ 16) were randomized 220 to receive either olanzapine or placebo, in combination with their original therapy. Olanzapine 221 (in a dose range of 5-20 mg/day, once daily, starting at 10 mg/day) combined with lithium or 222 valproate (in a therapeutic range of 0.6 mEq/L to 1.2 mEq/L or 50 µg/mL to 125 µg/mL,

223 respectively) was superior to lithium or valproate alone in the reduction of Y-MRS total score.

(2) In a second 6-week placebo-controlled combination trial, 169 outpatients on lithium or 224

225 valproate therapy with inadequately controlled manic or mixed symptoms (Y-MRS \geq 16) were 226 randomized to receive either olanzapine or placebo, in combination with their original therapy.

227 Olanzapine (in a dose range of 5-20 mg/day, once daily, starting at 10 mg/day) combined with

228 lithium or valproate (in a therapeutic range of 0.6 mEq/L to 1.2 mEq/L or 50 μ g/mL to

229 125 µg/mL, respectively) was superior to lithium or valproate alone in the reduction of Y-MRS

230 total score.

231 Agitation Associated with Schizophrenia and Bipolar I Mania

232 The efficacy of intramuscular olanzapine for injection for the treatment of agitation was 233 established in 3 short-term (24 hours of IM treatment) placebo-controlled trials in agitated 234 inpatients from two diagnostic groups: schizophrenia and Bipolar I Disorder (manic or mixed 235 episodes). Each of the trials included a single active comparator treatment arm of either 236 haloperidol injection (schizophrenia studies) or lorazepam injection (bipolar mania study). 237 Patients enrolled in the trials needed to be: (1) judged by the clinical investigators as clinically 238 agitated and clinically appropriate candidates for treatment with intramuscular medication, and 239 (2) exhibiting a level of agitation that met or exceeded a threshold score of ≥ 14 on the five items

- 240 comprising the Positive and Negative Syndrome Scale (PANSS) Excited Component (i.e., poor
- impulse control, tension, hostility, uncooperativeness and excitement items) with at least
- one individual item score \geq 4 using a 1-7 scoring system (1=absent, 4=moderate, 7=extreme). In the studies, the mean baseline PANSS Excited Component score was 18.4, with scores ranging
- from 13 to 32 (out of a maximum score of 35), thus suggesting predominantly moderate levels of
- agitation with some patients experiencing mild or severe levels of agitation. The primary efficacy
- 246 measure used for assessing agitation signs and symptoms in these trials was the change from
- baseline in the PANSS Excited Component at 2 hours post-injection. Patients could receive up to
- three injections during the 24 hour IM treatment periods; however, patients could not receive the
- second injection until after the initial 2 hour period when the primary efficacy measure was assessed. The results of the trials follow:
- 251 (1) In a placebo-controlled trial in agitated inpatients meeting DSM-IV criteria for
- schizophrenia (n=270), four fixed intramuscular olanzapine for injection doses of 2.5 mg, 5 mg,
 7.5 mg and 10 mg were evaluated. All doses were statistically superior to placebo on the PANSS
 Excited Component at 2 hours post-injection. However, the effect was larger and more consistent
 for the three highest doses. There were no significant pairwise differences for the 7.5 and 10 mg
- 256 doses over the 5 mg dose.
 - (2) In a second placebo-controlled trial in agitated inpatients meeting DSM-IV criteria for
 schizophrenia (n=311), one fixed intramuscular olanzapine for injection dose of 10 mg was
 evaluated. Olanzapine for injection was statistically superior to placebo on the PANSS Excited
 - 260 Component at 2 hours post-injection.
 - 261 (3) In a placebo-controlled trial in agitated inpatients meeting DSM-IV criteria for Bipolar I
 - 262 Disorder (and currently displaying an acute manic or mixed episode with or without psychotic
- features) (n=201), one fixed intramuscular olanzapine for injection dose of 10 mg was evaluated.
- Olanzapine for injection was statistically superior to placebo on the PANSS Excited Component
 at 2 hours post-injection.
- Examination of population subsets (age, race, and gender) did not reveal any differential responsiveness on the basis of these subgroupings.
- 268

INDICATIONS AND USAGE

269 Schizophrenia

- 270 Oral ZYPREXA is indicated for the treatment of schizophrenia.
- The efficacy of ZYPREXA was established in short-term (6-week) controlled trials of schizophrenic inpatients (*see* CLINICAL PHARMACOLOGY).
- 273 The effectiveness of oral ZYPREXA at maintaining a treatment response in schizophrenic
- 274 patients who had been stable on ZYPREXA for approximately 8 weeks and were then followed
- for a period of up to 8 months has been demonstrated in a placebo-controlled trial (*see*
- 276 CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use ZYPREXA for
- extended periods should periodically re-evaluate the long-term usefulness of the drug for the
- 278 individual patient (see DOSAGE AND ADMINISTRATION).

279 Bipolar Disorder

- <u>Acute Monotherapy</u> Oral ZYPREXA is indicated for the treatment of acute mixed or manic
 episodes associated with Bipolar I Disorder.
- 282 The efficacy of ZYPREXA was established in two placebo-controlled trials (one 3-week and
- 283 one 4-week) with patients meeting DSM-IV criteria for Bipolar I Disorder who currently
- displayed an acute manic or mixed episode with or without psychotic features (*see* CLINICAL
 PHARMACOLOGY).
- 286 <u>Maintenance Monotherapy</u> The benefit of maintaining bipolar patients on monotherapy with 287 oral ZYPREXA after achieving a responder status for an average duration of two weeks was 288 demonstrated in a controlled trial (are Clinical Efficiency Data and or CLINICAL
- demonstrated in a controlled trial (see Clinical Efficacy Data under CLINICAL
- PHARMACOLOGY). The physician who elects to use ZYPREXA for extended periods should
 periodically re-evaluate the long-term usefulness of the drug for the individual patient (*see* DOSAGE AND ADMINISTRATION).
- 292 <u>Combination Therapy</u> The combination of oral ZYPREXA with lithium or valproate is
 293 indicated for the short-term treatment of acute mixed or manic episodes associated with Bipolar I
 294 Disorder.
- 295 The efficacy of ZYPREXA in combination with lithium or valproate was established in
- two placebo-controlled (6-week) trials with patients meeting DSM-IV criteria for Bipolar I
- 297 Disorder who currently displayed an acute manic or mixed episode with or without psychotic
- 298 features (*see* CLINICAL PHARMACOLOGY).

299 Agitation Associated with Schizophrenia and Bipolar I Mania

- ZYPREXA IntraMuscular is indicated for the treatment of agitation associated with
 schizophrenia and bipolar I mania. "Psychomotor agitation" is defined in DSM-IV as "excessive
- 302 motor activity associated with a feeling of inner tension." Patients experiencing agitation often 303 manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors,
- escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the
- 305 use of intramuscular antipsychotic medications to achieve immediate control of the agitation.
- The efficacy of ZYPREXA IntraMuscular for the treatment of agitation associated with schizophrenia and bipolar I mania was established in 3 short-term (24 hours) placebo-controlled trials in agitated inpatients with schizophrenia or Bipolar I Disorder (manic or mixed episodes)
- 309 (see CLINICAL PHARMACOLOGY).
- 310

CONTRAINDICATIONS

- 311 ZYPREXA is contraindicated in patients with a known hypersensitivity to the product.
- 312 For specific information about the contraindications of lithium or valproate, refer to the
- 313 CONTRAINDICATIONS section of the package inserts for these other products.

WARNINGS 314 **Increased Mortality in Elderly Patients with Dementia-Related Psychosis** — Elderly 315 patients with dementia-related psychosis treated with atypical antipsychotic drugs are at 316 317 an increased risk of death compared to placebo. ZYPREXA is not approved for the 318 treatment of patients with dementia-related psychosis (see BOX WARNING). 319 In placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the 320 incidence of death in olanzapine-treated patients was significantly greater than placebo-treated 321 patients (3.5% vs 1.5%, respectively). 322 Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients with Dementia-Related 323 Psychosis — Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including 324 fatalities, were reported in patients in trials of olanzapine in elderly patients with 325 dementia-related psychosis. In placebo-controlled trials, there was a significantly higher 326 incidence of cerebrovascular adverse events in patients treated with olanzapine compared to

patients treated with placebo. Olanzapine is not approved for the treatment of patients withdementia-related psychosis.

329 Hyperglycemia and Diabetes Mellitus — Hyperglycemia, in some cases extreme and associated 330 with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with 331 atypical antipsychotics including olanzapine. Assessment of the relationship between atypical 332 antipsychotic use and glucose abnormalities is complicated by the possibility of an increased 333 background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence 334 of diabetes mellitus in the general population. Given these confounders, the relationship between 335 atypical antipsychotic use and hyperglycemia-related adverse events is not completely 336 understood. However, epidemiological studies suggest an increased risk of treatment-emergent 337 hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical 338 339 antipsychotics are not available. 340 Patients with an established diagnosis of diabetes mellitus who are started on atypical

antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical

347 antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has 348 resolved when the atypical antipsychotic was discontinued; however, some patients required 349 resolved when the atypical antipsychotic was discontinued; however, some patients required 340 resolved when the atypical antipsychotic was discontinued; however, some patients required 341 resolved when the atypical antipsychotic was discontinued; however, some patients required 342 resolved when the atypical antipsychotic was discontinued; however, some patients required 343 resolved when the atypical antipsychotic was discontinued; however, some patients required 344 resolved when the atypical antipsychotic was discontinued; however, some patients required 345 resolved when the atypical antipsychotic was discontinued; however, some patients required 346 resolved when the atypical antipsychotic was discontinued; however, some patients required 347 resolved when the atypical antipsychotic was discontinued; however, some patients required 348 resolved when the atypical antipsychotic was discontinued; however, some patients required 349 resolved when the atypical antipsychotic was discontinued; however, some patients required 349 resolved when the atypical antipsychotic was discontinued; however, some patients required 349 resolved when the atypical antipsychotic was discontinued; however, some patients required 340 resolved when the atypical attraction at the source of the source

349 continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

<u>Neuroleptic Malignant Syndrome (NMS)</u> — A potentially fatal symptom complex sometimes
 referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with
 administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are
 hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability
 (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional
 signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute

356 renal failure.

357 The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a

diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential
 reintroduction of drug therapy should be carefully considered. The patient should be carefully
 monitored, since recurrences of NMS have been reported.

<u>Tardive Dyskinesia</u> — A syndrome of potentially irreversible, involuntary, dyskinetic
 movements may develop in patients treated with antipsychotic drugs. Although the prevalence of
 the syndrome appears to be highest among the elderly, especially elderly women, it is impossible
 to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which

375 patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their

376 potential to cause tardive dyskinesia is unknown.

377 The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are

- believed to increase as the duration of treatment and the total cumulative dose of antipsychotic
 drugs administered to the patient increase. However, the syndrome can develop, although much
 less commonly, after relatively brief treatment periods at low doses.
- There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
- Given these considerations, olanzapine should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients (1) who suffer from a chronic illness that is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful
- treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response
- 392 should be sought. The need for continued treatment should be reassessed periodically.
- If signs and symptoms of tardive dyskinesia appear in a patient on olanzapine, drug
 discontinuation should be considered. However, some patients may require treatment with
 olanzapine despite the presence of the syndrome.
- For specific information about the warnings of lithium or valproate, refer to the WARNINGS section of the package inserts for these other products.
- 398

PRECAUTIONS

399 General

400 <u>Hemodynamic Effects</u> — Olanzapine may induce orthostatic hypotension associated with 401 dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration 402 period, probably reflecting its α_1 -adrenergic antagonistic properties. Hypotension, bradycardia 403 with or without hypotension, tachycardia, and syncope were also reported during the clinical 404 trials with intramuscular olanzapine for injection. In an open-label clinical pharmacology study in 405 non-agitated patients with schizophrenia in which the safety and tolerability of intramuscular

- 406 olanzapine were evaluated under a maximal dosing regimen (three 10 mg doses administered
- 407 4 hours apart), approximately one-third of these patients experienced a significant orthostatic
- 408 decrease in systolic blood pressure (i.e., decrease \geq 30 mmHg) (see DOSAGE AND 400 ADMINISTRATION). Summary was reported in 0.6% (15/2500) of elementing tracted
- 409 ADMINISTRATION). Syncope was reported in 0.6% (15/2500) of olanzapine-treated patients in 410 phase 2-3 oral olanzapine studies and in 0.3% (2/722) of olanzapine-treated patients with
- 411 agitation in the intramuscular olanzapine for injection studies. Three normal volunteers in
- 412 phase 1 studies with intramuscular olanzapine experienced hypotension, bradycardia, and sinus
- 412 phase 1 studies with infulnitisedial ofalizaphie experienced hypotension, or adyedicia, and s 413 pauses of up to 6 seconds that spontaneously resolved (in 2 cases the events occurred on
- 414 intramuscular olanzapine, and in 1 case, on oral olanzapine). The risk for this sequence of
- 415 hypotension, bradycardia, and sinus pause may be greater in nonpsychiatric patients compared to
- 416 psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs.
 417 For oral olanzapine therapy, the risk of orthostatic hypotension and syncope may be minimized
- 417 For oral oralizable therapy, the fisk of orthostatic hypotension and syncope may be minimized
 418 by initiating therapy with 5 mg QD (*see* DOSAGE AND ADMINISTRATION). A more gradual
 419 titration to the target dose should be considered if hypotension occurs.
- 420 For intramuscular olanzapine for injection therapy, patients should remain recumbent if drowsy
- 421 or dizzy after injection until examination has indicated that they are not experiencing postural
- 422 hypotension, bradycardia, and/or hypoventilation.
- 423 Olanzapine should be used with particular caution in patients with known cardiovascular
 424 disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities),
 425 cerebrovascular disease, and conditions which would predispose patients to hypotension

426 (dehydration, hypovolemia, and treatment with antihypertensive medications) where the

427 occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased
 428 medical risk.

429 Caution is necessary in patients who receive treatment with other drugs having effects that can 430 induce hypotension, bradycardia, respiratory or central nervous system depression (see Drug 431 Interactions). Concomitant administration of intramuscular olanzapine and parenteral 432 benzodiazepine has not been studied and is therefore not recommended. If use of intramuscular 433 olanzapine in combination with parenteral benzodiazepines is considered, careful evaluation of 434 clinical status for excessive sedation and cardiorespiratory depression is recommended. 435 Seizures — During premarketing testing, seizures occurred in 0.9% (22/2500) of 436 olanzapine-treated patients. There were confounding factors that may have contributed to the 437 occurrence of seizures in many of these cases. Olanzapine should be used cautiously in patients 438 with a history of seizures or with conditions that potentially lower the seizure threshold, 439 e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in 440 a population of 65 years or older. 441 Hyperprolactinemia — As with other drugs that antagonize dopamine D_2 receptors, olanzapine 442 elevates prolactin levels, and a modest elevation persists during chronic administration. Tissue 443 culture experiments indicate that approximately one-third of human breast cancers are prolactin 444 dependent in vitro, a factor of potential importance if the prescription of these drugs is 445 contemplated in a patient with previously detected breast cancer of this type. Although 446 disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported 447 with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels 448 is unknown for most patients. As is common with compounds which increase prolactin release, 449 an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies 450 conducted in mice and rats (see Carcinogenesis). However, neither clinical studies nor 451 epidemiologic studies have shown an association between chronic administration of this class of 452 drugs and tumorigenesis in humans; the available evidence is considered too limited to be 453 conclusive. 454 Transaminase Elevations — In placebo-controlled studies, clinically significant ALT (SGPT) 455 elevations (\geq 3 times the upper limit of the normal range) were observed in 2% (6/243) of patients 456 exposed to olanzapine compared to none (0/115) of the placebo patients. None of these patients 457 experienced jaundice. In two of these patients, liver enzymes decreased toward normal despite continued treatment and in two others, enzymes decreased upon discontinuation of olanzapine. In 458 459 the remaining two patients, one, seropositive for hepatitis C, had persistent enzyme elevation for 460 four months after discontinuation, and the other had insufficient follow-up to determine if 461 enzymes normalized. 462 Within the larger premarketing database of about 2400 patients with baseline SGPT ≤ 90 IU/L, the incidence of SGPT elevation to >200 IU/L was 2% (50/2381). Again, none of these patients 463 464 experienced jaundice or other symptoms attributable to liver impairment and most had transient 465 changes that tended to normalize while olanzapine treatment was continued.

466 Among 2500 patients in oral olanzapine clinical trials, about 1% (23/2500) discontinued 467 treatment due to transaminase increases.

468 Caution should be exercised in patients with signs and symptoms of hepatic impairment, in
469 patients with pre-existing conditions associated with limited hepatic functional reserve, and in
470 patients who are being treated with potentially hepatotoxic drugs. Periodic assessment of
471 transaminases is recommended in patients with significant hepatic disease (*see* Laboratory Tests).

472 <u>Potential for Cognitive and Motor Impairment</u> — Somnolence was a commonly reported

473 adverse event associated with olanzapine treatment, occurring at an incidence of 26% in

474 olanzapine patients compared to 15% in placebo patients. This adverse event was also dose

475 related. Somnolence led to discontinuation in 0.4% (9/2500) of patients in the premarketing476 database.

477 Since olanzapine has the potential to impair judgment, thinking, or motor skills, patients should 478 be cautioned about operating hazardous machinery, including automobiles, until they are 479 reasonably certain that olanzapine therapy does not affect them adversely

reasonably certain that olanzapine therapy does not affect them adversely.

480 <u>Body Temperature Regulation</u> — Disruption of the body's ability to reduce core body

temperature has been attributed to antipsychotic agents. Appropriate care is advised when

482 prescribing olanzapine for patients who will be experiencing conditions which may contribute to 483 an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat,

484 receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

485 <u>Dysphagia</u> — Esophageal dysmotility and aspiration have been associated with antipsychotic
 486 drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with
 487 advanced Alzheimer's disease. Olanzapine and other antipsychotic drugs should be used

488 cautiously in patients at risk for aspiration pneumonia.

489 <u>Suicide</u> — The possibility of a suicide attempt is inherent in schizophrenia and in bipolar

490 disorder, and close supervision of high-risk patients should accompany drug therapy.

491 Prescriptions for olanzapine should be written for the smallest quantity of tablets consistent with 492 good patient management, in order to reduce the risk of overdose.

493 <u>Use in Patients with Concomitant Illness</u> — Clinical experience with olanzapine in patients
 494 with certain concomitant systemic illnesses (*see* Renal Impairment and Hepatic Impairment
 495 *under* CLINICAL PHARMACOLOGY, Special Populations) is limited.

Olanzapine exhibits in vitro muscarinic receptor affinity. In premarketing clinical trials with
 olanzapine, olanzapine was associated with constipation, dry mouth, and tachycardia, all adverse
 events possibly related to cholinergic antagonism. Such adverse events were not often the basis
 for discontinuations from olanzapine, but olanzapine should be used with caution in patients with

500 clinically significant prostatic hypertrophy, narrow angle glaucoma, or a history of paralytic ileus.

501 In five placebo-controlled studies of olanzapine in elderly patients with dementia-related 502 psychosis (n=1184), the following treatment-emergent adverse events were reported in

502 psychosis (n=1184), the following treatment-emergent adverse events were reported in 503 olanzapine-treated patients at an incidence of at least 2% and significantly greater than

504 placebo-treated patients: falls, somnolence, peripheral edema, abnormal gait, urinary

505 incontinence, lethargy, increased weight, asthenia, pyrexia, pneumonia, dry mouth and visual

506 hallucinations. The rate of discontinuation due to adverse events was significantly greater with

olanzapine than placebo (13% vs 7%). Elderly patients with dementia-related psychosis treated

508 with olanzapine are at an increased risk of death compared to placebo. Olanzapine is not

509 approved for the treatment of patients with dementia-related psychosis. If the prescriber elects to 510 treat elderly patients with dementia-related psychosis, vigilance should be exercised (*see* BOX

511 WARNING *and* WARNINGS).

512 Olanzapine has not been evaluated or used to any appreciable extent in patients with a recent 513 history of myocardial infarction or unstable heart disease. Patients with these diagnoses were

513 history of myocardial infarction or unstable heart disease. Patients with these diagnoses were 514 excluded from premarketing clinical studies. Because of the risk of orthostatic hypotension with

514 excluded from premarketing clinical studies. Because of the fisk of orthostatic hypotension 515 olanzapine, caution should be observed in cardiac patients (*see* Hemodynamic Effects).

515 For specific information about the precautions of lithium or valproate, refer to the

517 PRECAUTIONS section of the package inserts for these other products.

518 Information for Patients

519 Physicians are advised to discuss the following issues with patients for whom they prescribe 520 olanzapine:

521 <u>Orthostatic Hypotension</u> — Patients should be advised of the risk of orthostatic hypotension,

522 especially during the period of initial dose titration and in association with the use of

- 523 concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam or 524 alcohol (*see* Drug Interactions).
- 525 <u>Interference with Cognitive and Motor Performance</u> Because olanzapine has the potential to
- 526 impair judgment, thinking, or motor skills, patients should be cautioned about operating
- hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
 therapy does not affect them adversely.
- 529 <u>Pregnancy</u> Patients should be advised to notify their physician if they become pregnant or 530 intend to become pregnant during therapy with olanzapine.
- 531 <u>Nursing</u> Patients should be advised not to breast-feed an infant if they are taking olanzapine.
- 532 <u>Concomitant Medication</u> Patients should be advised to inform their physicians if they are 533 taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for 534 interactions.
- 535 <u>Alcohol</u> Patients should be advised to avoid alcohol while taking olanzapine.
- 536 <u>Heat Exposure and Dehydration</u> Patients should be advised regarding appropriate care in 537 avoiding overheating and dehydration.
- 538 <u>Phenylketonurics</u> ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains
- 539 phenylalanine (0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20 mg tablet, respectively).

540 Laboratory Tests

- 541 Periodic assessment of transaminases is recommended in patients with significant hepatic
- 542 disease (*see* Transaminase Elevations).

543 Drug Interactions

- 544 The risks of using olanzapine in combination with other drugs have not been extensively 545 evaluated in systematic studies. Given the primary CNS effects of olanzapine, caution should be 546 used when olanzapine is taken in combination with other centrally acting drugs and alcohol.
- 547 Because of its potential for inducing hypotension, olanzapine may enhance the effects of 548 certain antihypertensive agents.
- 549 Olanzapine may antagonize the effects of levodopa and dopamine agonists.
- 550 <u>The Effect of Other Drugs on Olanzapine</u> Agents that induce CYP1A2 or glucuronyl
- transferase enzymes, such as omeprazole and rifampin, may cause an increase in olanzapine
- clearance. Inhibitors of CYP1A2 could potentially inhibit olanzapine clearance. Although
- olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a
- 554 single enzyme may appreciably alter olanzapine clearance. Therefore, a dosage increase (for 555 induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs.
- 555 induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs. 556 Charcoal — The administration of activated charcoal (1 g) reduced the Cmax and AUC of oral
- 556 <u>Charcoal</u> The administration of activated charcoal (1 g) reduced the Cmax and AUC of oral 557 olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about
- 558 6 hours after dosing, charcoal may be a useful treatment for olanzapine overdose.
- 559 <u>Cimetidine and Antacids</u> Single doses of cimetidine (800 mg) or aluminum- and 560 magnesium-containing antacids did not affect the oral bioavailability of olanzapine.
- 561 <u>Carbamazepine</u> Carbamazepine therapy (200 mg bid) causes an approximately 50% increase
- in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a
 potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even
- 564 greater increase in olanzapine clearance.
- 565 <u>Ethanol</u> Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine 566 pharmacokinetics.
- 567 <u>Fluoxetine</u> Fluoxetine (60 mg single dose or 60 mg daily for 8 days) causes a small
- 568 (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%)
- 569 decrease in olanzapine clearance. The magnitude of the impact of this factor is small in

570 comparison to the overall variability between individuals, and therefore dose modification is not 571 routinely recommended.

572 <u>Fluvoxamine</u> — Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine.

573 This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female

nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%,

respectively. Lower doses of olanzapine should be considered in patients receiving concomitant

576 treatment with fluvoxamine.

577 <u>Warfarin</u> — Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics.

578 <u>Effect of Olanzapine on Other Drugs</u> — In vitro studies utilizing human liver microsomes

579 suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6,

and CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactionsmediated by these enzymes.

582 <u>Lithium</u> — Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of
 583 lithium. Therefore, concomitant olanzapine administration does not require dosage adjustment of
 584 lithium.

585 <u>Valproate</u> — Studies in vitro using human liver microsomes determined that olanzapine has 586 little potential to inhibit the major metabolic pathway, glucuronidation, of valproate. Further,

587 valproate has little effect on the metabolism of olanzapine in vitro. In vivo administration of

588 olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of

valproate. Therefore, concomitant olanzapine administration does not require dosage adjustmentof valproate.

- 591 Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active 592 metabolite desipramine, and warfarin. Multiple doses of olanzapine did not influence the kinetics 593 of diazepam and its active metabolite N-desmethyldiazepam, ethanol, or biperiden. However, the 594 co-administration of either diazepam or ethanol with olanzapine potentiated the orthostatic
- 595 hypotension observed with olanzapine. Multiple doses of olanzapine did not affect the

596 pharmacokinetics of theophylline or its metabolites.

597 <u>Lorazepam</u> — Administration of intramuscular lorazepam (2 mg) 1 hour after intramuscular 598 olanzapine for injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine,

598 olanzapine for injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine, 599 unconjugated lorazepam, or total lorazepam. However, this co-administration of intramuscular

600 lorazepam and intramuscular olanzapine for injection added to the somnolence observed with

601 either drug alone (*see* Hemodynamic Effects).

602 Carcinogenesis, Mutagenesis, Impairment of Fertility

603 <u>Carcinogenesis</u> — Oral carcinogenicity studies were conducted in mice and rats. Olanzapine

was administered to mice in two 78-week studies at doses of 3, 10, 30/20 mg/kg/day (equivalent to 0.8-5 times the maximum recommended human daily oral dose on a mg/m² basis) and 0.25, 2,

605 to 0.8-5 times the maximum recommended numan daily oral dose on a mg/m basis) and 0.25, 2, 606 8 mg/kg/day (equivalent to 0.06-2 times the maximum recommended human daily oral dose on a

 mg/m^2 basis). Rats were dosed for 2 years at doses of 0.25, 1, 2.5, 4 mg/kg/day (males) and 0.25,

1, 4, 8 mg/kg/day (females) (equivalent to 0.13-2 and 0.13-4 times the maximum recommended

human daily oral dose on a mg/m^2 basis, respectively). The incidence of liver hemangiomas and

610 hemangiosarcomas was significantly increased in one mouse study in female mice dosed at

8 mg/kg/day (2 times the maximum recommended human daily oral dose on a mg/m² basis).

612 These tumors were not increased in another mouse study in females dosed at 10 or

30/20 mg/kg/day (2-5 times the maximum recommended human daily oral dose on a mg/m²

basis); in this study, there was a high incidence of early mortalities in males of the

615 30/20 mg/kg/day group. The incidence of mammary gland adenomas and adenocarcinomas was

616 significantly increased in female mice dosed at $\geq 2 \text{ mg/kg/day}$ and in female rats dosed at

617 $\geq 4 \text{ mg/kg/day} (0.5 \text{ and } 2 \text{ times the maximum recommended human daily oral dose on a mg/m}^2$

- 618 basis, respectively). Antipsychotic drugs have been shown to chronically elevate prolactin levels
- 619 in rodents. Serum prolactin levels were not measured during the olanzapine carcinogenicity

620 studies; however, measurements during subchronic toxicity studies showed that olanzapine

621 elevated serum prolactin levels up to 4-fold in rats at the same doses used in the carcinogenicity

study. An increase in mammary gland neoplasms has been found in rodents after chronic

administration of other antipsychotic drugs and is considered to be prolactin mediated. The

relevance for human risk of the finding of prolactin mediated endocrine tumors in rodents is

625 unknown (*see* Hyperprolactinemia *under* PRECAUTIONS, General).

626 <u>Mutagenesis</u> — No evidence of mutagenic potential for olanzapine was found in the Ames 627 reverse mutation test, in vivo micronucleus test in mice, the chromosomal aberration test in

628 Chinese hamster ovary cells, unscheduled DNA synthesis test in rat hepatocytes, induction of

629 forward mutation test in mouse lymphoma cells, or in vivo sister chromatid exchange test in bone 630 marrow of Chinese hamsters

630 marrow of Chinese hamsters.

<u>Impairment of Fertility</u> — In an oral fertility and reproductive performance study in rats, male
 mating performance, but not fertility, was impaired at a dose of 22.4 mg/kg/day and female

633 fertility was decreased at a dose of 3 mg/kg/day (11 and 1.5 times the maximum recommended

human daily oral dose on a mg/m^2 basis, respectively). Discontinuance of olanzapine treatment

reversed the effects on male mating performance. In female rats, the precoital period was

636 increased and the mating index reduced at 5 mg/kg/day (2.5 times the maximum recommended

- human daily oral dose on a mg/m² basis). Diestrous was prolonged and estrous delayed at 11 mg/m^2 basis).
- $1.1 \text{ mg/kg/day} (0.6 \text{ times the maximum recommended human daily oral dose on a mg/m² basis);$
- 639 therefore olanzapine may produce a delay in ovulation.

640 **Pregnancy**

- $\frac{\text{Pregnancy Category C}}{\text{Pregnancy Category C}} \text{In oral reproduction studies in rats at doses up to 18 mg/kg/day and}$
- 642 in rabbits at doses up to 30 mg/kg/day (9 and 30 times the maximum recommended human daily
- oral dose on a mg/m^2 basis, respectively) no evidence of teratogenicity was observed. In an oral rat teratology study, early resorptions and increased numbers of nonviable fetuses were observed
- 644 rat teratology study, early resorptions and increased numbers of nonviable fetuses were observed 645 at a dose of 18 mg/kg/day (9 times the maximum recommended human daily oral dose on a
- mg/m^2 basis). Gestation was prolonged at 10 mg/kg/day (5 times the maximum recommended number of a dose of a mg/m² basis).
- 647 human daily oral dose on a mg/m² basis). In an oral rabbit teratology study, fetal toxicity
- 648 (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic
- dose of 30 mg/kg/day (30 times the maximum recommended human daily oral dose on a mg/m²
- 650 basis).
- 651 Placental transfer of olanzapine occurs in rat pups.
- 652 There are no adequate and well-controlled trials with olanzapine in pregnant females.
- 653 Seven pregnancies were observed during clinical trials with olanzapine, including 2 resulting in
- normal births, 1 resulting in neonatal death due to a cardiovascular defect, 3 therapeutic
- abortions, and 1 spontaneous abortion. Because animal reproduction studies are not always
- 656 predictive of human response, this drug should be used during pregnancy only if the potential
- benefit justifies the potential risk to the fetus.

658 Labor and Delivery

659 Parturition in rats was not affected by olanzapine. The effect of olanzapine on labor and delivery in humans is unknown.

661 Nursing Mothers

- In a study in lactating, healthy women, olanzapine was excreted in breast milk. Mean infant
- dose at steady state was estimated to be 1.8% of the maternal olanzapine dose. It is recommended
 that women receiving olanzapine should not breast-feed.

665 Pediatric Use

666 Safety and effectiveness in pediatric patients have not been established.

667 Geriatric Use

680

668 Of the 2500 patients in premarketing clinical studies with oral olanzapine, 11% (263) were

669 65 years of age or over. In patients with schizophrenia, there was no indication of any different

tolerability of olanzapine in the elderly compared to younger patients. Studies in elderly patients

671 with dementia-related psychosis have suggested that there may be a different tolerability profile 672 in this population compared to younger patients with schizophrenia. Elderly patients with

673 dementia-related psychosis treated with olanzapine are at an increased risk of death compared to

674 placebo. Olanzapine is not approved for the treatment of patients with dementia-related

- psychosis. If the prescriber elects to treat elderly patients with dementia-related psychosis,
- 676 vigilance should be exercised. Also, the presence of factors that might decrease pharmacokinetic
- 677 clearance or increase the pharmacodynamic response to olanzapine should lead to consideration
- of a lower starting dose for any geriatric patient (see BOX WARNING, WARNINGS,
- 679 PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

681 The information below is derived from a clinical trial database for olanzapine consisting of

682 8661 patients with approximately 4165 patient-years of exposure to oral olanzapine and

683 722 patients with exposure to intramuscular olanzapine for injection. This database includes:

684 (1) 2500 patients who participated in multiple-dose oral olanzapine premarketing trials in

schizophrenia and Alzheimer's disease representing approximately 1122 patient-years of

exposure as of February 14, 1995; (2) 182 patients who participated in oral olanzapine

687 premarketing bipolar mania trials representing approximately 66 patient-years of exposure; 688 (3) 191 patients who participated in an oral olanzapine trial of patients having various psychiati

688 (3) 191 patients who participated in an oral olanzapine trial of patients having various psychiatric 689 symptoms in association with Alzheimer's disease representing approximately 29 patient-years

690 of exposure; (4) 5788 patients from 88 additional oral olanzapine clinical trials as of

691 December 31, 2001; and (5) 722 patients who participated in intramuscular olanzapine for

692 injection premarketing trials in agitated patients with schizophrenia, Bipolar I Disorder (manic or

mixed episodes), or dementia. In addition, information from the premarketing 6-week clinical

694 study database for olanzapine in combination with lithium or valproate, consisting of

695 224 patients who participated in bipolar mania trials with approximately 22 patient-years of 696 exposure, is included below.

The conditions and duration of treatment with olanzapine varied greatly and included (in
overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients,
fixed-dose and dose-titration studies, and short-term or longer-term exposure. Adverse reactions
were assessed by collecting adverse events, results of physical examinations, vital signs, weights,
laboratory analytes, ECGs, chest x-rays, and results of ophthalmologic examinations.

laboratory analytes, ECGs, chest x-rays, and results of ophthalmologic examinations.
 Certain portions of the discussion below relating to objective or numeric safety parameters,

- namely, dose-dependent adverse events, vital sign changes, weight gain, laboratory changes, and
 ECG changes are derived from studies in patients with schizophrenia and have not been
 duplicated for bipolar mania or agitation. However, this information is also generally applicable
- duplicated for bipolar mania or agitation. However, this information is also generally application
 to bipolar mania and agitation.

Adverse events during exposure were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard COSTART dictionary terminology has been used

712 initially to classify reported adverse events.

The stated frequencies of adverse events represent the proportion of individuals who

real experienced, at least once, a treatment-emergent adverse event of the type listed. An event was

considered treatment emergent if it occurred for the first time or worsened while receiving

therapy following baseline evaluation. The reported events do not include those event terms that

- 717 were so general as to be uninformative. Events listed elsewhere in labeling may not be repeated
- below. It is important to emphasize that, although the events occurred during treatment with
- olanzapine, they were not necessarily caused by it. The entire label should be read to gain acomplete understanding of the safety profile of olanzapine.
- The prescriber should be aware that the figures in the tables and tabulations cannot be used to
- 722 predict the incidence of side effects in the course of usual medical practice where patient
- characteristics and other factors differ from those that prevailed in the clinical trials. Similarly,
- the cited frequencies cannot be compared with figures obtained from other clinical investigations
- involving different treatments, uses, and investigators. The cited figures, however, do provide the
- 726 prescribing physician with some basis for estimating the relative contribution of drug and
- nondrug factors to the adverse event incidence in the population studied.

Incidence of Adverse Events in Short-Term, Placebo-Controlled and Combination Trials

- The following findings are based on premarketing trials of (1) oral olanzapine for
- 731 schizophrenia, bipolar mania, a subsequent trial of patients having various psychiatric symptoms
- in association with Alzheimer's disease, and premarketing combination trials, and
- (2) intramuscular olanzapine for injection in agitated patients with schizophrenia or bipolarmania.
- Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials
- 737 <u>Schizophrenia</u> Overall, there was no difference in the incidence of discontinuation due to
- adverse events (5% for oral olanzapine vs 6% for placebo). However, discontinuations due to
- increases in SGPT were considered to be drug related (2% for oral olanzapine vs 0% for placebo)

740 (*see* PRECAUTIONS).

- 741 <u>Bipolar Mania Monotherapy</u> Overall, there was no difference in the incidence of
- discontinuation due to adverse events (2% for oral olanzapine vs 2% for placebo).
- 743 <u>Agitation</u> Overall, there was no difference in the incidence of discontinuation due to adverse 744 events (0.4% for intramuscular olanzapine for injection vs 0% for placebo).
- 745 Adverse Events Associated with Discontinuation of Treatment in Short-Term
- 746 Combination Trials
- 747 <u>Bipolar Mania Combination Therapy</u> In a study of patients who were already tolerating
- rates events were events were
- 11% for the combination of oral olanzapine with lithium or valproate compared to 2% for
- patients who remained on lithium or valproate monotherapy. Discontinuations with the
- combination of oral olanzapine and lithium or valproate that occurred in more than 1 patient
- were: somnolence (3%), weight gain (1%), and peripheral edema (1%).
- 753 Commonly Observed Adverse Events in Short-Term, Placebo-Controlled Trials
- The most commonly observed adverse events associated with the use of oral olanzapine
- 755 (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated
- patients (olanzapine incidence at least twice that for placebo) were:
- 757

Common Treatment-Emergent Adverse Events Associated with the				
Use of Oral Olanzapine in 6-Week Trials — SCHIZOPHRENIA				
Percentage of Patients Reporting Event				
Adverse Event	Olanzapine Placebo			
	(N=248)	(N=118)		
Postural hypotension 5 2				

Constipation	9	3	
Weight gain	6	1	
Dizziness	11	4	
Personality disorder ¹	8	4	
Akathisia	5	1	
¹ Personality disorder is the COSTART term for designating non-aggressive objectionable behavior.			

⁷⁵⁸ 759

Common Treatment-Emergent Adverse Events Associated with the					
Use of Oral Olanzapir	Use of Oral Olanzapine in 3-Week and 4-Week Trials — BIPOLAR MANIA				
	Percentage of Patients Reporting Event				
Adverse Event	Olanzapine	Placebo			
	(N=125)	(N=129)			
Asthenia	15	6			
Dry mouth	22	7			
Constipation	11	5			
Dyspepsia	11	5			
Increased appetite	6	3			
Somnolence	35	13			
Dizziness	18	6			
Tremor	6	3			

760

761 There was one adverse event (somnolence) observed at an incidence of 5% or greater among

intramuscular olanzapine for injection-treated patients and not observed at an equivalent
 incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo)

during the placebo-controlled premarketing studies. The incidence of somnolence during the

765 24 hour IM treatment period in clinical trials in agitated patients with schizophrenia or bipolar

766 mania was 6% for intramuscular olanzapine for injection and 3% for placebo.

Adverse Events Occurring at an Incidence of 2% or More Among Oral Olanzapine Treated Patients in Short-Term, Placebo-Controlled Trials

- Table 1 enumerates the incidence, rounded to the nearest percent, of treatment-emergent
- adverse events that occurred in 2% or more of patients treated with oral olanzapine (doses
- $\geq 2.5 \text{ mg/day}$) and with incidence greater than placebo who participated in the acute phase of placebo-controlled trials.
- 773

Table 1 Treatment-Emergent Adverse Events: Incidence in Short-Term, Placebo-Controlled Clinical Trials¹ with Oral Olanzapine

	Percentage of Patients Reporting Event		
Body System/Adverse Event	Olanzapine (N=532)	Placebo (N=294)	
Body as a Whole			
Accidental injury	12	8	
Asthenia	10	9	
Fever	6	2	
Back pain	5	2	

Chest pain	3	1
Cardiovascular System		
Postural hypotension	3	1
Tachycardia	3	1
Hypertension	2	1
Digestive System		
Dry mouth	9	5
Constipation	9	4
Dyspepsia	7	5
Vomiting	4	3
Increased appetite	3	2
Hemic and Lymphatic System		
Ecchymosis	5	3
Metabolic and Nutritional Disorders		
Weight gain	5	3
Peripheral edema	3	1
Musculoskeletal System		
Extremity pain (other than joint)	5	3
Joint pain	5	3
Nervous System		
Somnolence	29	13
Insomnia	12	11
Dizziness	11	4
Abnormal gait	6	1
Tremor	4	3
Akathisia	3	2
Hypertonia	3	2
Articulation impairment	2	1
Respiratory System		
Rhinitis	7	6
Cough increased	6	3
Pharyngitis	4	3
Special Senses		
Amblyopia	3	2
Urogenital System		
Urinary incontinence	2	1
Urinary tract infection	2	1

¹ Events reported by at least 2% of patients treated with olanzapine, except the following events which had an Events reported by at least 2% of patients treated with oralizaphie, except the following events which had an incidence equal to or less than placebo: abdominal pain, agitation, anorexia, anxiety, apathy, confusion, depression, diarrhea, dysmenorrhea², hallucinations, headache, hostility, hyperkinesia, myalgia, nausea, nervousness, paranoid reaction, personality disorder³, rash, thinking abnormal, weight loss.
 ² Denominator used was for females only (olanzapine, N=201; placebo, N=114).
 ³ Personality disorder is the COSTART term for designating non-aggressive objectionable behavior.

- 781 Commonly Observed Adverse Events in Short-Term Combination Trials
- 782 In the bipolar mania combination placebo-controlled trials, the most commonly observed
- adverse events associated with the combination of olanzapine and lithium or valproate (incidence of \geq 5% and at least twice placebo) were:
- 785

Common Treatment-Emergent Adverse Events Associated with the				
Use of Oral Olanzapin	e in 6-Week Combination Trials			
	0	nts Reporting Event		
Adverse Event	Olanzapine with	Placebo with		
	lithium or valproate	lithium or valproate		
	(N=229)	(N=115)		
Dry mouth	32	9		
Weight gain	26	7		
Increased appetite	24	8		
Dizziness	14	7		
Back pain	8	4		
Constipation	8	4		
Speech disorder	7 1			
Increased salivation	6	2		
Amnesia	5	2		
Paresthesia	5	2		

786

787 Adverse Events Occurring at an Incidence of 2% or More Among Oral Olanzapine-

788 Treated Patients in Short-Term Combination Trials

Table 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent

adverse events that occurred in 2% or more of patients treated with the combination of

olanzapine (doses \geq 5 mg/day) and lithium or valproate and with incidence greater than lithium or

valproate alone who participated in the acute phase of placebo-controlled combination trials.

793

Table 2

Treatment-Emergent Adverse Events: Incidence in Short-Term, Placebo-Controlled Combination Clinical Trials¹

with Oral Olanzapine

	Percentage of Patients Reporting Event			
Body System/Adverse Event	Olanzapine with lithium or valproate (N=229)	Placebo with lithium or valproate (N=115)		
Body as a Whole				
Asthenia	18	13		
Back pain	8	4		
Accidental injury	4	2		
Chest pain	3	2		
Cardiovascular System				
Hypertension	2	1		
Digestive System				
Dry mouth	32	9		

	T 1 //	24	0
	Increased appetite	24	8
	Thirst	10	6
	Constipation	8	4
	Increased salivation	6	2
	Metabolic and Nutritional Disorders	2.6	-
	Weight gain	26	7
	Peripheral edema	6	4
	Edema	2	1
	Nervous System		
	Somnolence	52	27
	Tremor	23	13
	Depression	18	17
	Dizziness	14	7
	Speech disorder	7	1
	Amnesia	5	2
	Paresthesia	5	2
	Apathy	4	3
	Confusion	4	1
	Euphoria	3	2
	Incoordination	2	0
	Respiratory System		
	Pharyngitis	4	1
	Dyspnea	3	1
	Skin and Appendages		
	Sweating	3	1
	Acne	2	0
	Dry skin	2	0
	Special Senses		
	Amblyopia	9	5
	Abnormal vision	2	0
	Urogenital System		
	Dysmenorrhea ²	2	0
	Vaginitis ²	2	0
794 795 796 797 798 799 800 801 802 803	 ¹ Events reported by at least 2% of patients treated w incidence equal to or less than placebo: abdominal akathisia, anorexia, anxiety, arthralgia, cough incre flu syndrome, headache, hostility, insomnia, libido nausea, nervousness, pain, paranoid reaction, perso vomiting. ² Denominator used was for females only (olanzapine For specific information about the adverse to the ADVERSE REACTIONS section of t 	pain, abnormal dreams, abnormal ased, diarrhea, dyspepsia, emotio decreased, libido increased, mens nality disorder, rash, rhinitis, slee e, N=128; placebo, N=51).	ejaculation, agitation, nal lability, fever, flatulence, strual disorder ² , myalgia, p disorder, thinking abnormal,
804 805 806 807	Adverse Events Occurring at an Inciden Olanzapine for Injection-Treated Patient Table 3 enumerates the incidence, rounded adverse events that occurred in 1% or more	ts in Short-Term, Placebo	o-Controlled Trials reatment-emergent

- 808 injection (dose range of 2.5-10 mg/injection) and with incidence greater than placebo who
- 809 participated in the short-term, placebo-controlled trials in agitated patients with schizophrenia or 810 bipolar mania.
- 811

Table 3

Treatment-Emergent Adverse Events: Incidence in Short-Term (24 Hour), Placebo-Controlled Clinical Trials with Intramuscular Olanzapine for Injection in Agitated Patients with Schizophrenia or Bipolar Mania¹

-	Percentage of Patients Reporting Event		
Body System/Adverse Event	Olanzapine (N=415)	Placebo (N=150)	
Body as a Whole	i		
Asthenia	2	1	
Cardiovascular System			
Hypotension	2	0	
Postural hypotension	1	0	
Nervous System			
Somnolence	6	3	
Dizziness	4	2	
Tremor	1	0	

812 ¹ Events reported by at least 1% of patients treated with olanzapine for injection, except the following events which 813 had an incidence equal to or less than placebo: agitation, anxiety, dry mouth, headache, hypertension, insomnia, 814 nervousness.

815

816 Additional Findings Observed in Clinical Trials

- 817 The following findings are based on clinical trials.
- 818 Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled Trials
- Extrapyramidal Symptoms The following table enumerates the percentage of patients with 819
- 820 treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal
- rating scales during acute therapy in a controlled clinical trial comparing oral olanzapine at 821
- 822 3 fixed doses with placebo in the treatment of schizophrenia.
- 823

TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY RATING SCALES INCIDENCE IN A FIXED DOSAGE RANGE, PLACEBO-CONTROLLED CLINICAL TRIAL OF ORAL OLANZAPINE IN SCHIZOPHRENIA — ACUTE PHASE*

	Percentage of Patients Reporting Event			
	Olanzapine Olanzapine Olanzapine			
	Placebo	5 ± 2.5 mg/day	$10 \pm 2.5 \text{ mg/day}$	15 ± 2.5 mg/day
Parkinsonism ¹	15	14	12	14
Akathisia ²	23	16	19	27

* No statistically significant differences.

824 825 ¹ Percentage of patients with a Simpson-Angus Scale total score >3.

826 ² Percentage of patients with a Barnes Akathisia Scale global score ≥ 2 .

827

- 828 The following table enumerates the percentage of patients with treatment-emergent
- 829 extrapyramidal symptoms as assessed by spontaneously reported adverse events during acute

- 830 therapy in the same controlled clinical trial comparing olanzapine at 3 fixed doses with placebo
- 831 in the treatment of schizophrenia.
- 832

TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY ADVERSE EVENTS INCIDENCE IN A FIXED DOSAGE RANGE, PLACEBO-CONTROLLED CLINICAL TRIAL OF ORAL OLANZAPINE IN SCHIZOPHRENIA — ACUTE PHASE

	Percentage of Patients Reporting Event				
		Olanzapine Olanzapine Olanzapine			
	Placebo	5 ± 2.5 mg/day	10 ± 2.5 mg/day	15 ± 2.5 mg/day	
	(N=68)	(N=65)	(N=64)	(N=69)	
Dystonic events ¹	1	3	2	3	
Parkinsonism events ²	10	8	14	20	
Akathisia events ³	1	5	11*	10*	
Dyskinetic events ⁴	4	0	2	1	
Residual events ⁵	1	2	5	1	
Any extrapyramidal event	16	15	25	32*	

* Statistically significantly different from placebo.

- 833 834 ¹ Patients with the following COSTART terms were counted in this category: dystonia, generalized spasm, neck 835 rigidity, oculogyric crisis, opisthotonos, torticollis.
- 836 ² Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, 837
 - extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor.
- ³ Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia. 838 839 ⁴ Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, 840 choreoathetosis, dyskinesia, tardive dyskinesia.
- ⁵ Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, 841 842 twitching.
- 843

844 The following table enumerates the percentage of patients with treatment-emergent

- 845 extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during
- 846 controlled clinical trials comparing fixed doses of intramuscular olanzapine for injection with
- placebo in agitation. Patients in each dose group could receive up to three injections during the 847
- 848 trials (see CLINICAL PHARMACOLOGY). Patient assessments were conducted during the
- 849 24 hours following the initial dose of intramuscular olanzapine for injection. There were no
- 850 statistically significant differences from placebo.
- 851

TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY RATING SCALES INCIDENCE IN A FIXED DOSE, PLACEBO-CONTROLLED CLINICAL TRIAL OF INTRAMUSCULAR OLANZAPINE FOR INJECTION IN AGITATED PATIENTS WITH SCHIZOPHRENIA*

	Percentage of Patients Reporting Event					
	Olanzapine Olanzapine Olanzapine Olanzapine					
		IM	IM	IM	IM	
	Placebo	2.5 mg	5 mg	7.5 mg	10 mg	
Parkinsonism ¹	0	0	0	0	3	
Akathisia ²	0	0	5	0	0	

852 * No statistically significant differences.

853 ¹ Percentage of patients with a Simpson-Angus total score >3.

- ² Percentage of patients with a Barnes Akathisia Scale global score ≥ 2 . 854
- 855

- 856 The following table enumerates the percentage of patients with treatment-emergent
- 857 extrapyramidal symptoms as assessed by spontaneously reported adverse events in the same
- 858 controlled clinical trial comparing fixed doses of intramuscular olanzapine for injection with
- 859 placebo in agitated patients with schizophrenia. There were no statistically significant differences from placebo.
- 860
- 861

TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY ADVERSE EVENTS INCIDENCE IN A FIXED DOSE, PLACEBO-CONTROLLED CLINICAL TRIAL OF INTRAMUSCULAR OLANZAPINE FOR INJECTION IN AGITATED PATIENTS WITH SCHIZOPHRENIA*

	Percentage of Patients Reporting Event				
		Olanzapine	Olanzapine	Olanzapine	Olanzapine
		IM	IM	IM	IM
	Placebo	2.5 mg	5 mg	7.5 mg	10 mg
	(N=45)	(N=48)	(N=45)	(N=46)	(N=46)
Dystonic events ¹	0	0	0	0	0
Parkinsonism events ²	0	4	2	0	0
Akathisia events ³	0	2	0	0	0
Dyskinetic events ⁴	0	0	0	0	0
Residual events ⁵	0	0	0	0	0
Any extrapyramidal event	0	4	2	0	0

862 * No statistically significant differences.

863 Patients with the following COSTART terms were counted in this category: dystonia, generalized spasm, neck 864 rigidity, oculogyric crisis, opisthotonos, torticollis.

865 ² Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, 866

extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor.

867 Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia.

868 ⁴ Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, 869 choreoathetosis, dyskinesia, tardive dyskinesia.

870 Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, 871 twitching.

872

873 Other Adverse Events — The following table addresses dose relatedness for other adverse 874 events using data from a schizophrenia trial involving fixed dosage ranges of oral olanzapine. It

875 enumerates the percentage of patients with treatment-emergent adverse events for the

three fixed-dose range groups and placebo. The data were analyzed using the Cochran-Armitage 876

877 test, excluding the placebo group, and the table includes only those adverse events for which

878 there was a statistically significant trend.

879

	Percentage of Patients Reporting Event					
		Olanzapine	Olanzapine	Olanzapine		
Adverse Event	Placebo	5 ± 2.5 mg/day	10 ± 2.5 mg/day	15 ± 2.5 mg/day		
	(N=68)	(N=65)	(N=64)	(N=69)		
Asthenia	15	8	9	20		
Dry mouth	4	3	5	13		
Nausea	9	0	2	9		
Somnolence	16	20	30	39		
Tremor	3	0	5	7		

Vital Sign Changes — Oral olanzapine was associated with orthostatic hypotension and
 tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with

883 bradycardia, hypotension, and tachycardia in clinical trials (see PRECAUTIONS).

884 Weight Gain — In placebo-controlled, 6-week studies, weight gain was reported in 5.6% of 885 olanzapine patients compared to 0.8% of placebo patients. Olanzapine patients gained an average 886 of 2.8 kg, compared to an average 0.4 kg weight loss in placebo patients; 29% of olanzapine 887 patients gained greater than 7% of their baseline weight, compared to 3% of placebo patients. A 888 categorization of patients at baseline on the basis of body mass index (BMI) revealed a 889 significantly greater effect in patients with low BMI compared to normal or overweight patients; 890 nevertheless, weight gain was greater in all 3 olanzapine groups compared to the placebo group. 891 During long-term continuation therapy with olanzapine (238 median days of exposure), 56% of 892 olanzapine patients met the criterion for having gained greater than 7% of their baseline weight. 893 Average weight gain during long-term therapy was 5.4 kg. 894 Laboratory Changes — An assessment of the premarketing experience for olanzapine revealed

an association with asymptomatic increases in SGPT, SGOT, and GGT (*see* PRECAUTIONS).
 Olanzapine administration was also associated with increases in serum prolactin (*see* PRECAUTIONS), with an asymptomatic elevation of the eosinophil count in 0.3% of patients,

and with an increase in CPK.

899 Given the concern about neutropenia associated with other psychotropic compounds and the

900 finding of leukopenia associated with the administration of olanzapine in several animal models

901 (*see* ANIMAL TOXICOLOGY), careful attention was given to examination of hematologic 902 parameters in premarketing studies with olanzapine. There was no indication of a risk of

903 clinically significant neutropenia associated with olanzapine treatment in the premarketing

904 database for this drug.

905 In clinical trials among olanzapine-treated patients with random triglyceride levels of 906 <150 mg/dL at baseline (N=659), 0.5% of patients experienced triglyceride levels of $\geq 500 \text{ mg/dL}$ 907 anytime during the trials. In these same trials, olanzapine-treated patients (N=1185) had a mean

908 increase of 20 mg/dL in triglycerides from a mean baseline value of 175 mg/dL.

909 In placebo-controlled trials, olanzapine-treated patients with random cholesterol levels of

910 <200 mg/dL at baseline (N=1034) experienced cholesterol levels of \geq 240 mg/dL anytime during

911 the trials more often than placebo-treated patients (N=602) (3.6% vs 2.2%, respectively). In these

- same trials, olanzapine-treated patients (N=2528) had a mean increase of 0.4 mg/dL in
- 913 cholesterol from a mean baseline value of 203 mg/dL, which was significantly different
- 914 compared to placebo-treated patients (N=1415) with a mean decrease of 4.6 mg/dL from a mean p_{15} baseline value of 203 mg/dL
- 915 baseline value of 203 mg/dL.
- 916 *ECG Changes* Between-group comparisons for pooled placebo-controlled trials revealed no 917 statistically significant olanzapine/placebo differences in the proportions of patients experiencing
- potentially important changes in ECG parameters, including QT, QTc, and PR intervals.
- 919 Olanzapine use was associated with a mean increase in heart rate of 2.4 beats per minute
- 920 compared to no change among placebo patients. This slight tendency to tachycardia may be
- 921 related to olanzapine's potential for inducing orthostatic changes (see PRECAUTIONS).

922 Other Adverse Events Observed During the Clinical Trial Evaluation of 923 Olanzapine

Following is a list of terms that reflect treatment-emergent adverse events reported by patients

treated with oral olanzapine (at multiple doses $\geq 1 \text{ mg/day}$) in clinical trials (8661 patients,

4165 patient-years of exposure). This listing may not include those events already listed in

927 previous tables or elsewhere in labeling, those events for which a drug cause was remote, those

928 event terms which were so general as to be uninformative, and those events reported only once or

929 twice which did not have a substantial probability of being acutely life-threatening.

930 Events are further categorized by body system and listed in order of decreasing frequency 931 according to the following definitions: frequent adverse events are those occurring in at least 932 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials 933 appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients;

934 rare events are those occurring in fewer than 1/1000 patients.

935 **Body as a Whole** — *Frequent:* dental pain and flu syndrome; *Infrequent:* abdomen enlarged, 936 chills, face edema, intentional injury, malaise, moniliasis, neck pain, neck rigidity, pelvic pain, 937 photosensitivity reaction, and suicide attempt; Rare: chills and fever, hangover effect, and 938 sudden death.

939 **Cardiovascular System** — *Frequent:* hypotension; *Infrequent:* atrial fibrillation, bradycardia, 940 cerebrovascular accident, congestive heart failure, heart arrest, hemorrhage, migraine, pallor, 941 palpitation, vasodilatation, and ventricular extrasystoles; Rare: arteritis, heart failure, and 942 pulmonary embolus.

943 **Digestive System** — *Frequent:* flatulence, increased salivation, and thirst;

944 Infrequent: dysphagia, esophagitis, fecal impaction, fecal incontinence, gastritis, gastroenteritis,

945 gingivitis, hepatitis, melena, mouth ulceration, nausea and vomiting, oral moniliasis, periodontal

946 abscess, rectal hemorrhage, stomatitis, tongue edema, and tooth caries; *Rare:* aphthous

947 stomatitis, enteritis, eructation, esophageal ulcer, glossitis, ileus, intestinal obstruction, liver fatty 948 deposit, and tongue discoloration.

949 **Endocrine System** — *Infrequent:* diabetes mellitus; *Rare:* diabetic acidosis and goiter.

950 Hemic and Lymphatic System — Infrequent: anemia, cyanosis, leukocytosis, leukopenia, 951 lymphadenopathy, and thrombocytopenia; *Rare:* normocytic anemia and thrombocythemia.

952 Metabolic and Nutritional Disorders — Infrequent: acidosis, alkaline phosphatase increased, bilirubinemia, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hyperuricemia, 953 954 hypoglycemia, hypokalemia, hyponatremia, lower extremity edema, and upper extremity edema;

955 *Rare:* gout, hyperkalemia, hypernatremia, hypoproteinemia, ketosis, and water intoxication.

956 **Musculoskeletal System** — *Frequent:* joint stiffness and twitching; *Infrequent:* arthritis, 957 arthrosis, leg cramps, and myasthenia; *Rare:* bone pain, bursitis, myopathy, osteoporosis, and 958 rheumatoid arthritis.

959 **Nervous System** — *Frequent:* abnormal dreams, amnesia, delusions, emotional lability,

960 euphoria, manic reaction, paresthesia, and schizophrenic reaction; *Infrequent*: akinesia, alcohol 961 misuse, antisocial reaction, ataxia, CNS stimulation, cogwheel rigidity, delirium, dementia, 962 depersonalization, dysarthria, facial paralysis, hypesthesia, hypokinesia, hypotonia,

963

incoordination, libido decreased, libido increased, obsessive compulsive symptoms, phobias,

964 somatization, stimulant misuse, stupor, stuttering, tardive dyskinesia, vertigo, and withdrawal

965 syndrome; *Rare:* circumoral paresthesia, coma, encephalopathy, neuralgia, neuropathy, 966 nystagmus, paralysis, subarachnoid hemorrhage, and tobacco misuse.

967 **Respiratory System** — *Frequent:* dyspnea; *Infrequent:* apnea, asthma, epistaxis, hemoptysis, hyperventilation, hypoxia, laryngitis, and voice alteration; *Rare:* atelectasis, hiccup, 968

969 hypoventilation, lung edema, and stridor.

970 **Skin and Appendages** — *Frequent:* sweating; *Infrequent:* alopecia, contact dermatitis, dry 971 skin, eczema, maculopapular rash, pruritus, seborrhea, skin discoloration, skin ulcer, urticaria, 972 and vesiculobullous rash; *Rare:* hirsutism and pustular rash.

973 **Special Senses** — *Frequent:* conjunctivitis; *Infrequent:* abnormality of accommodation,

974 blepharitis, cataract, deafness, diplopia, dry eyes, ear pain, eye hemorrhage, eye inflammation,

975 eye pain, ocular muscle abnormality, taste perversion, and tinnitus; *Rare:* corneal lesion,

976 glaucoma, keratoconjunctivitis, macular hypopigmentation, miosis, mydriasis, and pigment

977 deposits lens. 978 **Urogenital System** — *Frequent:* vaginitis*; *Infrequent:* abnormal ejaculation*, amenorrhea*,

- breast pain, cystitis, decreased menstruation*, dysuria, female lactation*, glycosuria,
- 980 gynecomastia, hematuria, impotence*, increased menstruation*, menorrhagia*, metrorrhagia*,
- polyuria, premenstrual syndrome*, pyuria, urinary frequency, urinary retention, urinary urgency,
 urination impaired, uterine fibroids enlarged*, and vaginal hemorrhage*; *Rare:* albuminuria,
- 982 urination impaired, uterine fibroids enlarged*, and vaginal hemorrhage*; *Rare:* albuminum
 983 breast enlargement, mastitis, and oliguria.
- 984 * Adjusted for gender.
- 985

Following is a list of terms that reflect treatment-emergent adverse events reported by patients treated with intramuscular olanzapine for injection (at one or more doses ≥ 2.5 mg/injection) in clinical trials (722 patients). This listing may not include those events already listed in previous tables or elsewhere in labeling, those events for which a drug cause was remote, those event terms which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening.

- Events are further categorized by body system and listed in order of decreasing frequency
- according to the following definitions: frequent adverse events are those occurring in at least
- 994 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials 995 appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients.
- Body as a Whole *Frequent:* injection site pain; *Infrequent:* abdominal pain and fever.
- 997 **Cardiovascular System** *Infrequent:* AV block, heart block, and syncope.
- 998 **Digestive System** *Infrequent:* diarrhea and nausea.
- 999 Hemic and Lymphatic System Infrequent: anemia.
- 1000 Metabolic and Nutritional Disorders *Infrequent:* creatine phosphokinase increased,
- 1001 dehydration, and hyperkalemia.
- 1002 **Musculoskeletal System** *Infrequent:* twitching.
- 1003 Nervous System *Infrequent:* abnormal gait, akathisia, articulation impairment, confusion,
- 1004 and emotional lability.
- 1005 **Skin and Appendages** *Infrequent:* sweating.

1006 **Postintroduction Reports**

- 1007 Adverse events reported since market introduction that were temporally (but not necessarily 1008 causally) related to ZYPREXA therapy include the following: allergic reaction
- 1009 (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), diabetic coma, pancreatitis,
- 1010 priapism, rhabdomyolysis, and venous thromboembolic events (including pulmonary embolism
- and deep venous thrombosis). Random cholesterol levels of ≥ 240 mg/dL and random triglyceride
- 1012 levels of \geq 1000 mg/dL have been rarely reported.
- 1013

DRUG ABUSE AND DEPENDENCE

1014 Controlled Substance Class

- 1015 Olanzapine is not a controlled substance.
- 1016 Physical and Psychological Dependence
- 1017 In studies prospectively designed to assess abuse and dependence potential, olanzapine was 1018 shown to have acute depressive CNS effects but little or no potential of abuse or physical
- 1018 snown to have acute depressive CNS effects but little or no potential of abuse or physical 1019 dependence in rats administered oral doses up to 15 times the maximum recommended hu
- 1019 dependence in rats administered oral doses up to 15 times the maximum recommended human 1020 daily oral dose (20 mg) and rhesus monkeys administered oral doses up to 8 times the maximum
- 1021 recommended human daily oral dose on a mg/m² basis.
- Olanzapine has not been systematically studied in humans for its potential for abuse, tolerance,
 or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking
 behavior, these observations were not systematic, and it is not possible to predict on the basis of

this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or
abused once marketed. Consequently, patients should be evaluated carefully for a history of drug
abuse, and such patients should be observed closely for signs of misuse or abuse of olanzapine
(e.g., development of tolerance, increases in dose, drug-seeking behavior).

1026 (e.g., development of tolerance, increases in dose, drug-seeking benavio

1029

OVERDOSAGE

1030 Human Experience

In premarketing trials involving more than 3100 patients and/or normal subjects, accidental or intentional acute overdosage of olanzapine was identified in 67 patients. In the patient taking the largest identified amount, 300 mg, the only symptoms reported were drowsiness and slurred speech. In the limited number of patients who were evaluated in hospitals, including the patient taking 300 mg, there were no observations indicating an adverse change in laboratory analytes or ECG. Vital signs were usually within normal limits following overdoses.

In postmarketing reports of overdose with olanzapine alone, symptoms have been reported in
 the majority of cases. In symptomatic patients, symptoms with ≥10% incidence included
 agitation/aggressiveness, dysarthria, tachycardia, various extrapyramidal symptoms, and reduced
 level of consciousness ranging from sedation to coma. Among less commonly reported

- 1041 symptoms were the following potentially medically serious events: aspiration, cardiopulmonary
- arrest, cardiac arrhythmias (such as supraventricular tachycardia and one patient experiencing sinus pause with spontaneous resumption of normal rhythm), delirium, possible neuroleptic
- 1043 malignant syndrome, respiratory depression/arrest, convulsion, hypertension, and hypotension.
- 1045 Eli Lilly and Company has received reports of fatality in association with overdose of olanzapine
- 1046 alone. In one case of death, the amount of acutely ingested olanzapine was reported to be
- 1047 possibly as low as 450 mg; however, in another case, a patient was reported to survive an acute
- 1048 olanzapine ingestion of 1500 mg.

1049 Overdosage Management

1050 The possibility of multiple drug involvement should be considered. In case of acute 1051 overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation, 1052 which may include intubation. Gastric lavage (after intubation, if patient is unconscious) and 1053 administration of activated charcoal together with a laxative should be considered. The 1054 possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. Cardiovascular monitoring should 1055 1056 commence immediately and should include continuous electrocardiographic monitoring to detect 1057 possible arrhythmias.

1058 There is no specific antidote to olanzapine. Therefore, appropriate supportive measures should 1059 be initiated. Hypotension and circulatory collapse should be treated with appropriate measures 1060 such as intravenous fluids and/or sympathomimetic agents. (Do not use epinephrine, dopamine, 1061 or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen 1062 hypotension in the setting of olanzapine-induced alpha blockade.) Close medical supervision and

- 1063 monitoring should continue until the patient recovers.
- 1064

DOSAGE AND ADMINISTRATION

1065 Schizophrenia

1066 <u>Usual Dose</u> — Oral olanzapine should be administered on a once-a-day schedule without 1067 regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day 1068 within several days. Further dosage adjustments, if indicated, should generally occur at intervals

- 1069 of not less than 1 week, since steady state for olanzapine would not be achieved for
- 1070 approximately 1 week in the typical patient. When dosage adjustments are necessary, dose
- 1071 increments/decrements of 5 mg QD are recommended.

1072 Efficacy in schizophrenia was demonstrated in a dose range of 10 to 15 mg/day in clinical

1073 trials. However, doses above 10 mg/day were not demonstrated to be more efficacious than the

1074 10 mg/day dose. An increase to a dose greater than the target dose of 10 mg/day (i.e., to a dose of 1075 15 mg/day or greater) is recommended only after clinical assessment. The safety of doses above

1076 20 mg/day has not been evaluated in clinical trials.

1077 <u>Dosing in Special Populations</u> — The recommended starting dose is 5 mg in patients who are

1078 debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a

1079 combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking

1080 female patients ≥ 65 years of age), or who may be more pharmacodynamically sensitive to

1081 olanzapine (*see* CLINICAL PHARMACOLOGY; also *see* Use in Patients with Concomitant
 1082 Illness and Drug Interactions *under* PRECAUTIONS). When indicated, dose escalation should

1083 be performed with caution in these patients.

1084 <u>Maintenance Treatment</u> — While there is no body of evidence available to answer the question 1085 of how long the patient treated with olanzapine should remain on it, the effectiveness of oral

1086 olanzapine, 10 mg/day to 20 mg/day, in maintaining treatment response in schizophrenic patients

1087 who had been stable on ZYPREXA for approximately 8 weeks and were then followed for a

1088 period of up to 8 months has been demonstrated in a placebo-controlled trial (*see* CLINICAL

1089 PHARMACOLOGY). Patients should be periodically reassessed to determine the need for

1090 maintenance treatment with appropriate dose.

1091 Bipolar Disorder

- 1092 <u>Usual Monotherapy Dose</u> Oral olanzapine should be administered on a once-a-day schedule 1093 without regard to meals, generally beginning with 10 or 15 mg. Dosage adjustments, if indicated, 1094 should generally occur at intervals of not less than 24 hours, reflecting the procedures in the 1095 placebo-controlled trials. When dosage adjustments are necessary, dose increments/decrements
- 1096 of 5 mg QD are recommended.

1097 Short-term (3-4 weeks) antimanic efficacy was demonstrated in a dose range of 5 mg to 1098 20 mg/day in clinical trials. The safety of doses above 20 mg/day has not been evaluated in 1099 clinical trials.

1100 <u>Maintenance Monotherapy</u> — The benefit of maintaining bipolar patients on monotherapy with

1101 oral ZYPREXA at a dose of 5 to 20 mg/day, after achieving a responder status for an average

duration of two weeks, was demonstrated in a controlled trial (see Clinical Efficacy Data under

1103 CLINICAL PHARMACOLOGY). The physician who elects to use ZYPREXA for extended 1104 periods should periodically re-evaluate the long-term usefulness of the drug for the individual

1105 patient.

1106 <u>Bipolar Mania Usual Dose in Combination with Lithium or Valproate</u> — When administered

in combination with lithium or valproate, oral olanzapine dosing should generally begin with
 10 mg once-a-day without regard to meals.

1109 Short-term (6 weeks) antimanic efficacy was demonstrated in a dose range of 5 mg to

1110 20 mg/day in clinical trials. The safety of doses above 20 mg/day has not been evaluated in clinical trials.

- 1112 <u>Dosing in Special Populations</u> *See* Dosing in Special Populations *under* DOSAGE AND
 1113 ADMINISTRATION, Schizophrenia.
- 1114 Administration of ZYPREXA ZYDIS (olanzapine orally disintegrating tablets)
- 1115 After opening sachet, peel back foil on blister. Do not push tablet through foil. Immediately
- 1116 upon opening the blister, using dry hands, remove tablet and place entire ZYPREXA ZYDIS in
- 1117 the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed with or
- 1118 without liquid.

1119 Agitation Associated with Schizophrenia and Bipolar I Mania

- <u>Usual Dose for Agitated Patients with Schizophrenia or Bipolar Mania</u> The efficacy of
 intramuscular olanzapine for injection in controlling agitation in these disorders was
 demonstrated in a dose range of 2.5 mg to 10 mg. The recommended dose in these patients is
- 1123 10 mg. A lower dose of 5 or 7.5 mg may be considered when clinical factors warrant (see
- 1124 CLINICAL PHARMACOLOGY). If agitation warranting additional intramuscular doses persists
- following the initial dose, subsequent doses up to 10 mg may be given. However, the efficacy of
- repeated doses of intramuscular olanzapine for injection in agitated patients has not been systematically evaluated in controlled clinical trials. Also, the safety of total daily doses greater
- than 30 mg, or 10 mg injections given more frequently than 2 hours after the initial dose, and
- 1129 4 hours after the second dose have not been evaluated in clinical trials. Maximal dosing of
- 1130 intramuscular olanzapine (e.g., three doses of 10 mg administered 2-4 hours apart) may be
- associated with a substantial occurrence of significant orthostatic hypotension (see
- 1132 PRECAUTIONS, Hemodynamic Effects). Thus, it is recommended that patients requiring
- subsequent intramuscular injections be assessed for orthostatic hypotension prior to the administration of any subsequent doses of intramuscular olanzapine for injection. The
- administration of any subsequent doses of intramuscular of anzapine for injection. The administration of an additional dose to a patient with a clinically significant postural change in
- 1135 administration of an additional dose to a patient with a chinicarry significant postural change 1136 systolic blood pressure is not recommended.
- 1137 If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range
- 1137 If ongoing ofalizable therapy is chinearly indicated, or a ofalizable may be initiated in a range 1138 of 5-20 mg/day as soon as clinically appropriate (*see* Schizophrenia or Bipolar Disorder *under*
- 1139 DOSAGE AND ADMINISTRATION).
- 1140 Intramuscular Dosing in Special Populations A dose of 5 mg per injection should be
- 1141 considered for geriatric patients or when other clinical factors warrant. A lower dose of 2.5 mg
- 1142 per injection should be considered for patients who otherwise might be debilitated, be
- 1143 predisposed to hypotensive reactions, or be more pharmacodynamically sensitive to olanzapine
- 1144 (see CLINICAL PHARMACOLOGY; also see Use in Patients with Concomitant Illness and
- 1145 Drug Interactions *under* PRECAUTIONS).
- 1146 Administration of ZYPREXA IntraMuscular
- 1147 ZYPREXA IntraMuscular is intended for intramuscular use only. Do not administer 1148 intravenously or subcutaneously. Inject slowly, deep into the muscle mass.
- 1149 Parenteral drug products should be inspected visually for particulate matter and discoloration 1150 prior to administration, whenever solution and container permit.
- 1151 Directions for preparation of ZYPREXA IntraMuscular with Sterile Water for Injection
- 1152 Dissolve the contents of the vial using 2.1 mL of Sterile Water for Injection to provide a
- solution containing approximately 5 mg/mL of olanzapine. The resulting solution should appear
- 1154 clear and yellow. ZYPREXA IntraMuscular reconstituted with Sterile Water for Injection should
- be used immediately (within 1 hour) after reconstitution. **Discard any unused portion.**
- 1156 The following table provides injection volumes for delivering various doses of intramuscular
- 1157 olanzapine for injection reconstituted with Sterile Water for Injection.
- 1158

Dose, mg Olanzapine	Volume of Injection, mL		
10	Withdraw total contents of vial		
7.5	1.5		
5	1		
2.5	0.5		

1159

1160 Physical Incompatibility Information

- 1161 ZYPREXA IntraMuscular should be reconstituted only with Sterile Water for Injection.
- 1162 ZYPREXA IntraMuscular should not be combined in a syringe with diazepam injection because

- 1163 precipitation occurs when these products are mixed. Lorazepam injection should not be used to
- 1164 reconstitute ZYPREXA IntraMuscular as this combination results in a delayed reconstitution
- 1165 time. ZYPREXA IntraMuscular should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time. 1166
- 1167

HOW SUPPLIED

- 1168 The ZYPREXA 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets are white, round, and imprinted in
- blue ink with LILLY and tablet number. The 15 mg tablets are elliptical, blue, and debossed with 1169
- 1170 LILLY and tablet number. The 20 mg tablets are elliptical, pink, and debossed with LILLY and tablet number. The tablets are available as follows:
- 1171
- 1172

	TABLET STRENGTH					
	2.5 mg	5 mg	7.5 mg	10 mg	15 mg	20 mg
Tablet No.	4112	4115	4116	4117	4415	4420
Identification	LILLY	LILLY	LILLY	LILLY	LILLY	LILLY
	4112	4115	4116	4117	4415	4420
NDC Codes:						
Bottles 30	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-
	4112-30	4115-30	4116-30	4117-30	4415-30	4420-30
Bottles 60	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-
	4112-60	4115-60	4116-60	4117-60	4415-60	4420-60
Blisters -	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-
ID* 100	4112-33	4115-33	4116-33	4117-33	4415-33	4420-33
Bottles 1000	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-
	4112-04	4115-04	4116-04	4117-04	4415-04	4420-04
* Identi Dose [®] (unit dose medication Lilly)						

1173 * Identi-Dose[®] (unit dose medication, Lilly).

1174

1175 ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) are yellow, round, and debossed

1176 with the tablet strength. The tablets are available as follows:

1177

ZYPREXA ZYDIS	TABLET STRENGTH				
Tablets*	5 mg	10 mg	15 mg	20 mg	
Tablet No.	4453	4454	4455	4456	
Debossed	5	10	15	20	
NDC Codes:					
Dose Pack 30	NDC 0002-	NDC 0002-	NDC 0002-	NDC 0002-	
(Child-Resistant)	4453-85	4454-85	4455-85	4456-85	

1178

1179 ZYPREXA is a registered trademark of Eli Lilly and Company.

- 1180 ZYDIS is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries.
- *ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) is manufactured for Eli Lilly and 1181
- Company by Cardinal Health, United Kingdom, SN5 8RU. 1182
- 1183
- 1184 ZYPREXA IntraMuscular is available in:
- 1185 NDC 0002-7597-01 (No. VL7597) – 10 mg vial (1s)
- 1186 1187 Store ZYPREXA tablets, ZYPREXA ZYDIS, and ZYPREXA IntraMuscular vials (before
- reconstitution) at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. 1188

1189 Reconstituted ZYPREXA IntraMuscular may be stored at controlled room temperature, 1190 20° to 25°C (68° to 77°F) [see USP] for up to 1 hour if necessary. Discard any unused portion 1191 of reconstituted ZYPREXA IntraMuscular. The USP defines controlled room temperature as 1192 a temperature maintained thermostatically that encompasses the usual and customary working 1193 environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to 1194 be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that 1195 are experienced in pharmacies, hospitals, and warehouses. 1196 Protect ZYPREXA tablets and ZYPREXA ZYDIS from light and moisture. Protect 1197 ZYPREXA IntraMuscular from light, do not freeze. ANIMAL TOXICOLOGY 1198 1199 In animal studies with olanzapine, the principal hematologic findings were reversible 1200 peripheral cytopenias in individual dogs dosed at 10 mg/kg (17 times the maximum recommended human daily oral dose on a mg/m^2 basis), dose-related decreases in lymphocytes 1201 and neutrophils in mice, and lymphopenia in rats. A few dogs treated with 10 mg/kg developed 1202 1203 reversible neutropenia and/or reversible hemolytic anemia between 1 and 10 months of 1204 treatment. Dose-related decreases in lymphocytes and neutrophils were seen in mice given doses of 10 mg/kg (equal to 2 times the maximum recommended human daily oral dose on a mg/m² 1205 1206 basis) in studies of 3 months' duration. Nonspecific lymphopenia, consistent with decreased 1207 body weight gain, occurred in rats receiving 22.5 mg/kg (11 times the maximum recommended human daily oral dose on a mg/m² basis) for 3 months or 16 mg/kg (8 times the maximum 1208 1209 recommended human daily oral dose on a mg/m^2 basis) for 6 or 12 months. No evidence of bone 1210 marrow cytotoxicity was found in any of the species examined. Bone marrows were 1211 normocellular or hypercellular, indicating that the reductions in circulating blood cells were 1212 probably due to peripheral (non-marrow) factors. Literature revised September 30, 2005 1213 1214 Eli Lilly and Company 1215 Indianapólis, IN 46285, ÚSA 1216 www.ZYPREXA.com 1217 PV 5194 AMP PRINTED IN USA 1218 Copyright © 1997, 2005, Eli Lilly and Company. All rights reserved.